Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: Review and consensus statement

Supportive Care in Cancer

Volumn 19, Issue SUPPL. 1, 2011, Pages

  Einhorn, Lawrence H ^e   Grunberg, Steven M ^a   Rapoport, Bernardo ^b   Rittenberg, Cynthia ^c   Feyer, Petra ^d  

^a UNIVERSITY OF VERMONT   (United States)

^b Medical Oncology Centre of Rosebank   (South Africa)

^c Rittenberg Oncology Consulting   (United States)

^d Viventes Clinics Beniu Needcoellin   (Germany)

^e NONE

Author keywords

Antiemetics; Multiday chemotherapy; Rescue antiemetics

Indexed keywords

ANTIEMETIC AGENT; APREPITANT; BLEOMYCIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASETRON MESILATE; ETOPOSIDE; GRANISETRON; MELPHALAN; METOCLOPRAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; PALONOSETRON; SEROTONIN 3 ANTAGONIST; THIOTEPA;

ACNE; AGITATION; CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONFERENCE PAPER; EPIGASTRIC DISCOMFORT; HIGH DOSE CHEMOTHERAPY; HUMAN; INDIGESTION; INSOMNIA; LYMPHOMA; MULTIPLE DAY CHEMOTHERAPY; MYELOMA; NAUSEA AND VOMITING; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; STEM CELL TRANSPLANTATION; TESTIS CANCER; TREATMENT DURATION; WEIGHT GAIN;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; NAUSEA; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; STEM CELL TRANSPLANTATION; VOMITING;

EID: 79953293548     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-010-0920-z     Document Type: Conference Paper

References (24)

1. Einhorn LH, Rapoport B, Koeller J et al (2005) Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Supp Care Cancer 13:112-116 (Pubitemid 40558167)
2. Somerfield MR, Einhaus K, Hagerty KL et al (2008) American society of clinical oncology clinical practice guidelines: opportunities and challenges. J Clin Oncol 26:4022-4026
3. Herman TS, Einhorn LH, Jones SE et al (1979) Superiority of Nabilone over prochlorperazine as antiemetics in patients receiving chemotherapy. N Eng J Med 300:1295-1297 (Pubitemid 9219560)
4. Einhorn LH, Nagy C, Werner K et al (1990) Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy. J Clin Oncol 8:731-735 (Pubitemid 20127258)
5. Fox SM, Einhorn LH, Cox E et al (1993) Ondansetron versus ondansetron, dexamethasone and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy. J Clin Oncol 11:2391-2395 (Pubitemid 23353969)
6. Sledge GW, Einhorn LH, Nagy C et al (1992) Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer 70:2524-2528
7. Einhorn LH, Brames MJ, Dreicer R et al (2007) Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Supp Care Cancer 15:1293-1300 (Pubitemid 47583451)
8. Jordan K, Kinitz I, Voigt W et al (2009) Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer 45:1184-1187
9. Brames MJ, Johnson E, Nichols C et al (2009) Phase III study of granisetron + dexamethasone +/- aprepitant in patients with germ cell tumors undergoing 5 day courses of cisplatin-based combination chemotherapy: a Hoosier Oncology Group (H.O.G.) study. Supp Care Cancer 17:871-872, abstract
10. Baltzer L, Pisters KMW, Kris MG et al (1993) High dose ondansetron plus dexamethasone for the prevention of nausea and vomiting with multiple day cisplatin chemotherapy. Proc Amer Soc Clin Oncol 12:462, abstract
11. Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Brit J Cancer 94:1011-1015
12. Cook AM, Dzik-Jurasz Ask, Padhani AR, Norman A, Huddart RA (2001) The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumors. Brit J Cancer 85:1624-1626 (Pubitemid 34081503)
13. Ballen KK, Hesketh AM, Heyes C, Becker PS, Emmons RV, Fogarty K, LaPointe J, Liu Q, Hsieh CC, Hesketh PJ (2001) Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support. Bone Marrow Transplant 28:1061-1066 (Pubitemid 34030654)
14. López-Jiménez J, Martín-Ballesteros E, Sureda A, Uralburu C, Lorenzo I, del Campo R, Fernández C, Calbacho M, García-Belmonte D, Fernández G (2006) Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study. Haematologica 91:84-91
15. Mandanas RA, Beveridge R, Rifkin RM, Wallace H, Greenspan A, Asmar L (2005) A randomized, multicenter, open-label comparison of the antiemetic efficacy of dolasetron versus ondansetron for the prevention of nausea and vomiting during high-dose myeloablative chemotherapy. Support Cancer Ther 2:114-121
16. Paul B, Trovato JA, Thompson J, Badros AZ, Goloubeva O (2009) Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support. J Oncol Pharm Pract 16:45-51
17. Musso M, Scalone R, Crescimanno A, Bonanno V, Polizzi V, Porretto F, Bianchini C, Perrone T (2009) Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. Bone Marrow Transplant 45:123-127
18. Warr D (2008) Chemotherapy- and cancer-related nausea and vomiting. Curr Oncol 15:S4-S9
19. Choo SP, Kong KH, Lim WT, Gao F, Chua K, Leong SS (2006) Electroacupuncture for refractory acute emesis caused by chemotherapy. J Altern Complement Med 12:963-969 (Pubitemid 46095124)
20. Seynaeve C, de Mulder PH, Lane-Allman E, van Liessum PA, Verweij J (1991) The 5-HT3 receptor antagonist ondansetron re-establishes control in refractory emesis induced by non-cisplatin chemotherapy. Clin Oncol 3:199-203
21. Fabi A, Ciccarese M, Metro G, Savarese A, Giannarelli D, Nuzzo CM, Russillo M, Sperduti I, Carbone I, Bria E, Cognetti F (2008) Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study. Support Care Cancer 16:1375-1380
22. Rojas J, Stathis M, Thomas AG, Massuda EB, Alt J, Zhang J, Rubenstein E, Sebastiani S, Cantoreggi S, Snyder SH, Slusher B (2008) Palonosetron exhibits unique molecular interactions with the 5-HT 3 receptor. Anesth Analg 107:469-478
23. Hesketh PJ, Younger J, Sanz-Altamira P, Hayden M, Bushey J, Trainor B, Krentzin M, Nowd P, Arnaoutakis K, Hesketh AM (2009) Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide. Support Care Cancer 17:1065-1070
24. Oechsle K, Muller MR, Hartmann JT, Kanz L, Bokemeyer C (2006) Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT3 antagonists and dexamethasone. Onkologie 19:557-561 (Pubitemid 46005778)